Safety and Efficacy of KPI-121 Compared to Placebo in Subjects With Dry Eye Disease

Summary

The primary purpose of this study is to determine the efficacy and safety of KPI-121 0.25% ophthalmic suspension compared to vehicle (placebo) in subjects who have a documented clinical diagnosis of dry eye disease. The product will be studied over 14 days, with 1-2 drops instilled in each eye four times daily (QID).

Timeline

Start

2016-06

Primary completion

2017-09

Completion

2017-09

Drugs

Indications